Umbilical Cord Blood Stem Cells for HIE Treatment: Sofia’s Case Study

Key Case Details:

• Patient: Sofia, 2 years old (at the time of the injury), Khmelnytskyi region, Ukraine.
• Diagnosis: Severe hypoxic-ischemic encephalopathy (HIE) / CNS damage, seizures, persistent hypertonia, tube feeding.
• Cause: Asphyxia (drowning, submerged underwater for over 30 minutes).
• Treatment Method: Allogeneic transplantation of umbilical cord blood stem cells (from her biological sister).
• Number of Administrations: 2 infusions with a 1-year interval + comprehensive rehabilitation.
• Outcome: Cessation of seizures and significant improvement in neurological status, restoration of swallowing reflex, gradual recovery of basic self-care skills, independent walking, and socialization (education in a mainstream school).

Patient History: Tragically Severe and Critical Condition

In 2009, 3-year-old Sofia from the Khmelnytskyi region fell through the ice in a tragic accident. The child was in a state of clinical death (without respiration) for over 30 minutes.

Following prolonged resuscitation and being placed on mechanical ventilation (ventilator support), the girl emerged from the coma; however, her condition remained extremely critical. Traditional drug therapy during her six-month stay in the intensive care unit (ICU) yielded no improvement.

Clinical Presentation Prior to Stem Cell Therapy:

• Complete absence of voluntary movements (bedridden child, medically induced coma).
• Persistent increased muscle tone (rigidity) in both upper and lower extremities.
• Uncontrolled seizures that were refractory (unresponsive) to standard anticonvulsant treatment.
• Dysphagia (impaired swallowing) – nutrition was provided exclusively via a nasogastric tube.

Treatment Protocol and Recovery Stages

The treatment was comprehensive, combining advanced stem cell therapy with intensive physical therapy.

Timeline of Therapy:

• First Administration: Transfusion of umbilical cord blood stem cells from her sister. The initial positive changes appeared within just a few weeks – neurological deficits decreased, and seizures ceased completely.
• Two Months After the First Infusion: The girl swallowed food on her own for the first time, allowing for a gradual transition away from the nasogastric tube.
• Second Administration: Performed 1 year later to consolidate and enhance the regenerative effect.
• Rehabilitation: Continuous courses of kinesiotherapy and neurorehabilitation supported by the action of the stem cells, which served as the primary catalyst for brain tissue repair.

Long-term Outcome (17-year Follow-up)

Today, Sofia is a 19-year-old young woman living and studying in the UK, where she is preparing to enter college. Although she still experiences certain neurological and motor effects from the past injury, she walks independently, speaks clearly, and is successfully integrating into mainstream life.

Her critical neurological condition, which was previously deemed incurable and non-responsive to standard therapy, has been drastically improved due to the regenerative potential of umbilical cord blood stem cells.

Frequently Asked Questions about Stem Cell Therapy for Brain Injuries

• Can sibling cord blood be or umbilical cord MSCs used for HIE treatment?

Yes. Allogeneic transplantation using cord blood from a biological brother or sister has a high probability of immunological compatibility and is successfully used in regenerative therapy for neurological disorders.

• How do stem cells help with hypoxic-ischemic encephalopathy (HIE)?

Stem cells migrate to the injured areas of the brain, releasing neurotrophic factors, reducing chronic inflammation, stimulating angiogenesis, and promoting neuroplasticity to repair damaged tissues.

• What can I do if I don’t have a stored cord blood unit in a biobank?

If you do not have a privately stored deposit of stem cells, please contact us for a consultation. After assessing the patient’s condition and individual parameters, our specialists will be able to select the optimal treatment protocol using donor stem cells.